Chad K. Porter

A phase 2, randomised, placebo-controlled study to evaluate once-daily oral Travelan for the prevention of Travellers’ diarrhoea

Abstract This study evaluated once-daily oral dosing of Travelan (IMM-124E), a bovine polyclonal antibody product, for prevention of Enterotoxigenic Escherichia coli (ETEC)-induced diarrhoea. In this randomised, double-blind, placebo-controlled trial using an ETEC-controlled huma...